The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Limits of immunotherapy and need for biomarkers in gastric cancer
Shu-Qiang Yuan, MD, Sun Yat-sen University, Guangzhou, China, comments on the limitations of current immunotherapy approaches in locally advanced gastric or gastroesophageal junction (GEJ) cancer, noting that while they have improved survival, more than 50% of patients do not benefit from these treatments. Novel biomarkers beyond the current CPS score and dMMR tare needed to guide patient treatment strategies. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Firstly, I think even the immunotherapy with chemotherapy improved the pathological response rate, also the EFS and OS, but still more than 50% of patients did not benefit from the immunotherapy. But we don’t know which one, which patient, which population can benefit or not benefit. So in the future, I think, a new biomarker not only confined to the CPS score, but also the dMMR, but also some novel biomarkers should be discovered for guiding the patient treatment strategy...
Firstly, I think even the immunotherapy with chemotherapy improved the pathological response rate, also the EFS and OS, but still more than 50% of patients did not benefit from the immunotherapy. But we don’t know which one, which patient, which population can benefit or not benefit. So in the future, I think, a new biomarker not only confined to the CPS score, but also the dMMR, but also some novel biomarkers should be discovered for guiding the patient treatment strategy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
